|

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

RECRUITINGN/ASponsored by M.D. Anderson Cancer Center
Actively Recruiting
PhaseN/A
SponsorM.D. Anderson Cancer Center
Started2023-02-23
Est. completion2026-08-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT05676450

Summary

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Male/female patients who are at least 18 years of age on the day of informed consent signing.
2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
3. Provision of written informed consent for the study.
4. Pregnant women not included
5. Cognitively impaired adults are not included.

Exclusion Criteria:

None

Conditions2

CancerLymphoma

Locations2 sites

MD Anderson Cancer Center
Houston, Texas, 77030
Chijioke Nze, MD832-729-1752CCNze@mdanderson.org
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
San Antonio, Texas, 78229
Adolfo Enriques Diaz Duque, MD210-450-1209diazduque@uthscsa.edu

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.